Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 23, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
The filing details several transactions executed by the GlaxoSmithKline Employee Trust ("GSK Trust") on January 19 and January 22, 2007:
- January 19, 2007: Transferred 173,244 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- January 19, 2007: Sold 646 Ordinary Shares on behalf of participants in the GlaxoSmithKline Share Value Plan at GBP 14.05 per share.
- January 19, 2007: Transferred 2,168 Ordinary Shares to participants in the GlaxoSmithKline Share Value Plan.
- January 19, 2007: Received 4,500 Ordinary Shares due to the reversal of an incorrect exercise.
- January 22, 2007: Transferred 33,652 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the routine administration of employee share plans.
Key Facts for Investor Verification
- Verify the total number of shares transferred to employee option and share value plans during the reporting period.
- Confirm the transaction price of GBP 14.05 per share for the sale of 646 shares.
- Note that the GSK Trust is a discretionary trust for current and former employees, creating indirect interests for specific directors.
- Ensure the reversal of 4,500 shares due to an incorrect exercise is accounted for in internal records.